New FDA approvals and emerging trial data drive two pivotal 2026 NCCN guideline updates: lutetium-177 PSMA-617 for ...

The Nature Index 2025 Research Leaders — previously known as Annual Tables — reveal the leading institutions and countries/territories in the natural and health sciences, according to their output in ...

Top experts share the latest bladder, kidney and prostate cancer advances from the 2026 ASCO GU Symposium, highlighting ...

Dosimetry data from the Phase 3 ECLIPSE substudy demonstrated favorable organ radiation absorbed doses supporting administration of 7.4 GBq for up to six cycles BOSTON, Feb. 26, 2026 (GLOBE NEWSWIRE) ...

St Bartholomew's Hospital and The James Cook University Hospital mark key UK expansion of the company's Phase 2 mCRPC programme Dr Kenrick Ng, Medical Oncology Consultant, St Bartholomew's Hospital, ...

ASCO Rapid Recommendations Updates highlight revisions to select ASCO guideline recommendations as a response to the emergence of new and practice-changing data. The rapid updates are supported by an ...

Determinants of treatment intensification in metastatic hormone-sensitive prostate cancer: Institutional vs patient-level factors in a diverse UK multicentre cohort. This is an ASCO Meeting Abstract ...

OXFORD, United Kingdom, May 1, 2025 /PRNewswire/ -- Blue Earth Therapeutics today announced further progress in development of its radiohybrid, lutetium-labelled, PSMA targeted, investigational ...

SAN FRANCISCO -- Men with advanced prostate cancer and limited metastatic recurrence lived more than twice as long without disease progression when they received metastasis-directed radioactive ...

Petros Grivas, MD, PhD, expresses great enthusiasm for the 2025 ASCO Annual Meeting, highlighting its wealth of clinical trial data, educational sessions, and real-world insights. He is particularly ...